

00946

TORII PHARMACEUTICAL CO LTD

Address: 3-4-1 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8439

International tel: +81 (3) 3231-6811

International fax: +81 (3) 5203-7333

Website: www.torii.co.jp

Board of Directors: Norihiko Matsuo (President), Hiroshi Imai (Managing Director/Chief Pharmaceutical Marketing), Yuji Kagohashi (Director/Chief of R&D & Production), Hiroshi Kanaya (Executive Deputy President/Chief of Corporate Planning & Admin), Masanori Wada (Director/QA)

Senior Executives: Tadashi Kadota (Corporate Auditor), Yoshiaki Otsuka (Corporate Auditor), Yoshiyuki Taniguchi (Corporate Auditor), Hideo Yamaguchi (Corporate Auditor)

PRINCIPAL ACTIVITIES: Manufacture of pharmaceuticals

Trade Names: Futhan

Parent Company: Japan Tobacco Inc, Japan (00864)

Auditors: Deloitte Touche Tohmatsu

Ticker Symbol: 4551

Stock Exchange: Tokyo

Status: Public Company

Principal Shareholders: Japan Tobacco Inc (53.5%)

Date of Establishment: November 1921

No of Employees: 852

Financial Information:

	31.3.07	31.3.08
	¥'000	¥'000
Sales turnover	39,577,000	40,845,000
Profit before tax	5,434,000	5,379,000
Profit after tax	3,029,000	2,967,000
Dividend per share	26.0¥	30.0¥
Earnings per share	107.0¥	104.8¥
Share capital	5,190,000	5,190,000
Shareholders' equity	67,591,000	69,759,000

00947

TOWA PHARMACEUTICAL CO LTD

Address: 2-11 Shinbashi-cho, Kadoma 571-8580, Osaka Pref

International tel: +81 (6) 6900-9100

International fax: +81 (6) 6908-6060

Website: www.towayakuin.co.jp

Board of Directors: Itsuro Yoshida (President)

PRINCIPAL ACTIVITIES: Manufacture of drugs for respiratory and circulatory disorders

Branch Offices: Osaka; Hannan; Nagoya; Takarazuka; Itabashi; Koto; Setagaya; Tama; Fukuoka

Ticker Symbol: 4553

Stock Exchange: Tokyo

Status: Public Company

Principal Shareholders: Yoshida Jimsho (17.4%); Yoshida Kosan (11.6%); Yoshida Kikaku (8.8%); Itsuro Yoshida (5.9%)

Date of Establishment: April 1957

No of Employees: 1,125 (group)

Financial Information: Consolidated figures

	31.3.07	31.3.08
	¥'000	¥'000
Sales turnover	29,235,000	31,495,000
Profit after tax	2,600,000	2,690,000
Dividend per share	35.0¥	45.0¥
Earnings per share	151.3¥	156.9¥
Share capital	4,715,000	4,715,000
Shareholders' equity	33,270,000	34,940,000

00948

TOYAMA CHEMICAL CO LTD

Address: 3-2-5 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023

International tel: +81 (3) 3348-6611

International fax: +81 (3) 3348-6638

Telex: 2323150 TOYAMA J

Website: www.toyama-chemical.co.jp

Board of Directors: Katsuhiko Nakano (Chairman), Masuji Sugata (President), Shinichiro Inushima (Director), Shojo Kakimoto (Director), Yoshiharu Murotani (Director), Akira Ohira (Director), Hideo Sanada (Director/Senior Executive Officer), Yukio Yanagida (Director), Hiroichi Yoshida (Director)

PRINCIPAL ACTIVITIES: Manufacture and sale of pharmaceuticals, antibiotics and industrial chemicals

Trade Names: Ozex, Tomiron, Pentacillin, Tazocin, Cefoperazin, Tomiporan, Luprac, Flucam, Baxo, Abovis, Pirocut,

Rhythm, Kikuron, Kolberon, Tocks, Aoi Umi, Hakubiso, Mori No Kaori, Yanroncha, Shinkaiyumu

Branch Offices: Tokyo; New York, USA; London, UK

Subsidiary Companies: (100% owned unless stated):

HOKURIKU MEDICAL SERVICE CO LTD; Taiyo Sangyo Co Ltd; Tomix Co Ltd; TOYAMA EUROPE LTD (UK); Toyama Kouei Co Ltd; TOYAMA USA Inc (USA); White Public Relations Co Ltd

Auditors: Deloitte Touche Tohmatsu

Status: Private Company

Date of Establishment: 15 November 1936

No of Employees: 1,025

Financial Information: 2008: Consolidated

	31.3.07	31.3.08
	¥'000	¥'000
Sales turnover	16,732,000	27,060,000
Profit (loss) before tax	(6,911,000)	-
Profit (loss) after tax	(8,765,000)	480,000
Earnings (loss) per share	(44.68¥)	2.40¥
Share capital	22,400,000	22,400,000
Shareholders' equity	23,962,000	53,545,000

00949

TRANS GENIC INC

Address: 3-14-3 Minami-Kumamoto, Kumamoto-shi, Kumamoto 860-0812

International tel: +81 (96) 375-7660

International fax: +81 (96) 375-7661

Website: www.transgenic.co.jp

Board of Directors: Satoru Endo (Auditor), Toshio Kajima (Auditor), Masahiro Koreishi (President and Chief Executive Officer), Yasuhiko Matsuo (Internal Auditor), Michita Satoh (Director), Jun Tanaka (Executive Director), Ken-ichi Yamamura (Non-Executive Director)

PRINCIPAL ACTIVITIES: Analysis of genes and genetics information service

Principal Banks: Shoko Chukin Bank; The Bank of Tokyo-Mitsubishi UFJ Ltd

Auditors: Deloitte Touche Tohmatsu

Ticker Symbol: 2342

Stock Exchange: Tokyo

Status: Public Company

Date of Establishment: April 1998

No of Employees: 40

Financial Information:

	31.3.07	31.3.08
	¥'000	¥'000
Sales turnover	435,000	335,000
(Loss) after tax	(665,000)	(885,000)
(Loss) per share	(6091.0¥)	(8,110.0¥)
Share capital	4,855,000	4,855,000
Shareholders' equity	3,615,000	2,730,000

00950

TSUMURA & CO

Address: 2-17-11 Akasaka, Minato-ku, Tokyo 107-8521

International tel: +81 (3) 5574-6600

Website: www.tsumura.co.jp

Board of Directors: Junichi Yoshii (President)

PRINCIPAL ACTIVITIES: Manufacture and sale of pharmaceuticals, quasi-pharmaceuticals and toiletries

Branch Offices: Sapporo; Sendai; Tokyo; Nagoya; Osaka; Yokohama; Shizuoka; Kyoto; Kobe; Takamatsu; Tachikawa; Hiroshima and Fukuoka

Ticker Symbol: 4540

Stock Exchange: Tokyo

Status: Public Company

Principal Shareholders: Japan Trustee Services Bank

(12.6%); Master Trust Bank of Japan (5.7%)

Date of Establishment: 10 April 1893

No of Employees: 2,775 (group)

Financial Information: Consolidated figures

	31.3.07	31.3.08
	¥'000	¥'000
Sales turnover	91,225,000	94,800,000
Profit after tax	13,150,000	9,140,000
Dividend per share	17.0¥	23.0¥
Earnings per share	186.4¥	129.6¥
Share capital	19,485,000	19,485,000
Shareholders' equity	68,455,000	71,620,000

00951

VITAL-NET INC

Former name: Sun-S Inc

Address: 1-1 Ohtemachi, Aoba-ku, Sendai 980-8581

International tel: +81 (22) 266-4511

International fax: +81 (22) 218-6130

Website: www.vitalnet.co.jp

Board of Directors: Jun Suzuki (Chairman), Ken Suzuki (Representative Director)

PRINCIPAL ACTIVITIES: Wholesale trade in pharmaceuticals

Ticker Symbol: 9916

Stock Exchange: Tokyo

Status: Public Company

Principal Shareholders: Hikoji Suzuki (6.7%); Suzuhiko Ltd (5.2%)

Date of Establishment: February 1950

No of Employees: 2,220

Financial Information: Consolidated figures

	31.3.07	31.3.08
	¥'000	¥'000
Sales turnover	262,400,000	282,820,000
Profit after tax	1,070,000	1,310,000
Dividend per share	12.0¥	12.0¥
Earnings per share	26.7¥	32.9¥
Share capital	3,990,000	3,990,000
Shareholders' equity	36,440,000	36,325,000

00952

WAKAMOTO PHARMACEUTICAL CO LTD

Address: 1-5-3 Nihonbashi-Muromachi, Chuo-ku, Tokyo 103-8330

International tel: +81 (3) 3279-0371

International fax: +81 (3) 3279-0393

Website: www.wakamoto-pharm.co.jp

Board of Directors: Kiyooki Makita (Chairman), Takashi Ishii (President)

PRINCIPAL ACTIVITIES: Manufacture of pharmaceuticals

Ticker Symbol: 4512

Stock Exchange: Tokyo

Status: Public Company

Principal Shareholders: Kissei Pharmaceutical (9.5%); Brast-sheave Co (7.1%)

Date of Establishment: January 1933

No of Employees: 425 (group)

Financial Information: Consolidated figures

	31.3.07	31.3.08
	¥'000	¥'000
Sales turnover	10,325,000	10,170,000
Profit after tax	475,000	405,000
Dividend per share	5.0¥	5.0¥
Earnings per share	14.5¥	12.0¥
Share capital	3,395,000	3,395,000
Shareholders' equity	11,995,000	12,870,000

00953

WAKO PURE CHEMICALS INDUSTRIES LTD

Address: 3-1-2 Doshomachi, Chuo-ku, Osaka 540-8605

International tel: +81 (6) 6203-3741

International fax: +81 (6) 6203-2029

Website: www.wako-chem.co.jp

Board of Directors: Hajime Ikezoe (President), Synrou Kawamura (Senior Managing Executive Officer), Eisuke Kimura (Managing Executive Officer/GM Corporate Production/QA), Takeo Matsumoto (Managing Executive Officer/GM Corporate Admin & Personnel), Norimichi Ueno (Senior Managing Executive Officer), Yoshiharu Watabiki (Senior Managing Executive Officer/Purchasing)

Senior Executives: Shigeru Fukushima (Corporate Auditor), Eio Okayama (Corporate Auditor), Toyoji Yoshida (Corporate Auditor)

PRINCIPAL ACTIVITIES: Provision of laboratory chemicals, specialty chemicals and diagnostic reagents for genetic engineering research, tissue culture, measurement of environmental pollutants, immunological research, chromatography, organic syntheses and biochemical research

Subsidiary Companies: (100% owned unless stated): Wako Chemicals GmbH (Germany); Wako Chemicals USA Inc (USA)

Status: Private Company

Date of Establishment: 1922

No of Employees: 1,450

Indurgen, Lodine SR(TM), Mecloderm, Mecloderm F, Mep-tid(TM), Midon, Monocid*, PACIS(R), PENTASA(R), PROA-MATINE(R), Reminyl(TM), Rentibloc(R), Rentilin(R), SECOND LOOK, Sertagyn, Testimonia, Trandate, Trizivir(R), VERA-TRAN(R), Zeffix(R), Zefix

Subsidiary Companies: (100% owned unless stated): Shire BioChem, Inc (Canada); Shire Deutschland GmbH & Co KG (Germany); Shire France SA (France); Shire Human Generic Therapies (USA); Shire Italia SpA (Italy); Shire Pharmaceutical Contracts Ltd (Singapore); Shire Pharmaceuticals Group Ltd; Shire Pharmaceuticals Iberica SL (Spain); Shire Pharmaceuticals Ireland Ltd (Republic of Ireland); Shire US Manufacturing Inc (USA); Shire, Inc (USA)

Auditors: Deloitte & Touche LLP

Ticker Symbol: SHP

Stock Exchange: London

ISIN: GB00B0KQX869

Status: Public Company

Principal Shareholders: Legal & General Group plc (5.26%)

No of Employees: 3,436

Financial Information: 2006: Consolidated Figures; GAAP.
2007: Consolidated Figures; IFRS

	31.12.06	31.12.07
	US\$'000	US\$'000
Revenue	1,796,500	2,436,300
Profit before tax	129,600	31,400
Profit after tax	56,200	82,400
Dividend	32,400	41,300
Dividend per share	7.18c	8.62c
Earnings per share	11.0c	15.0c
Share capital	43,700	48,700
Shareholders' equity	4,145,400	5,218,600

03192

SIGMA PHARMACEUTICAL PLC

Address: 1 Colonial Way, Imperial Way, Watford WD2 4LA

International tel: +44 (1923) 444 999

International fax: +44 (1923) 444 998

Company email: info@sigma.co.uk

Website: www.sigpharm.co.uk

Board of Directors: B K H Shah (Chairman and Managing Director)

Management: Mrs D K Shah (Manager), Mrs K Shah (Secretary), M H Shah (Finance Director), Mrs J Shah (Manager)

Senior Executives: K H Shah (Company Secretary)

PRINCIPAL ACTIVITIES: Wholesale trade in pharmaceuticals

Principal Banks: National Westminster Bank plc

Auditors: King & King

Status: Non Quoted Public Company

No of Employees: 173

03193

SKYEPHARMA PLC

Address: 105 Piccadilly, London W1J 7NJ

International tel: +44 (20) 7491 1777

International fax: +44 (20) 7491 3338

Website: www.skyepharma.com

Company Registration Number: 107582

Board of Directors: Jeremy Scudamore (Chairman), Frank Condella (Chief Executive Officer), Alan Bray (Non-Executive Director), Dr Ken Cunningham (Chief Operating Officer), Peter Grant (Finance Director), Stephen Harris (Non-Executive Director), Dr Argeris Karabelas (Non-Executive Director), John Murphy (Company Secretary), Jean-Charles Tschudin (Non-Executive Director)

PRINCIPAL ACTIVITIES: Research, development, manufacture and sale of prescription drugs

Divestments: In March 2007 the Group disposed of its In-jectable Business.

Trade Names: Paxil CR, Xatral OD, Madopar DR, Coruno, Nifedipine, Diclofenac, Dilacor XR, Requip, Statin NK-104, Foradil DPI, Formoterol HFA, Pulmicort HFA, Formoterol Combi, DepoCyt, DepoMorphine, DepoBupivacaine, Psoraxine, Interferon alpha-2b, HGH, Solaraze, Hyclinda, Acyclovir, Propofol IDD-D, Busulfan, Fenofibrate, Multiple

Subsidiary Companies: (100% owned unless stated): Jago Holding AG (Switzerland); Jagotec AG (Switzerland); Krypton Ltd (Gibraltar); SkePharma AG (Switzerland); SkePharma Canada Inc (Canada); SkyPharma AB (Sweden); SkyPharma Holding AG (Switzerland); SkyPharma Holding Inc (USA); SkyPharma (Jersey) Ltd; SkyPharma Production SAS (France); SkyPharma US Inc (USA)

Principal Banks: HSBC Bank Plc

Auditors: Ernst & Young LLP

Principal Law Firm: Fasken Martineau Stringer Saul LLP;

Clifford Chance LLP

Ticker Symbol: SKP

Stock Exchange: London

Ticker Symbol 2: SKPW

Status: Public Company

Principal Shareholders: HBM BioVentures (Cayman) Ltd

(11.13%); Aviva Plc (10.31%)

No of Employees: 350

Financial Information: Consolidated figures

	31.12.06	31.12.07
	£'000	£'000
Sales turnover	43,000	41,600
Profit (loss) before tax	17,900	(3,000)
(Loss) after tax	(77,700)	(27,000)
(Loss) per share	(10.4p)	(3.5p)
Share capital	76,600	82,700
Shareholders' (deficit)	(48,400)	(59,200)

03194

SOURCE BIOSCIENCE PLC

Former name: Medical Solutions plc

Address: 1 Orchard Place, Nottingham Business Park, Nottingham NG8 6PX

International tel: +44 (115) 973 9012

International fax: +44 (115) 973 9013

Website: www.sourcebioscience.com

Company Registration Number: 0079136

Board of Directors: Laurie Turnbull (Chairman), Dr Nick Ash (Managing Director), Dr Sue Foden (Non-Executive Director), Dr Nick Leaves (Operations Director), Robin Slinger (Non-Executive Director), Dr Thomas Weaver (Commercial Director)

PRINCIPAL ACTIVITIES: The Group is a holding company and the principal activities of the subsidiaries are the marketing and sale of microscopy hardware and software and image analysis and management systems, development of intellectual property in cancer diagnosis/prognosis systems and the development, support and assembly of diagnostic telepathology workstations and the supply of a range of chemicals, consumables, provision of specialist pathology services, laboratory instruments and software for histopathology laboratories. Manufacture and supply of infection and contamination control products to the hospital and pharmaceutical industry and dermatology

Mergers and Acquisitions: In April 2007 Source BioScience plc acquired 40% of the ordinary share capital of the private healthcare provider Number One Health Group Limited. In July 2007 Source BioScience plc completed the acquisition of the entire ordinary share capital of Geneservice Limited.

Subsidiary Companies: (100% owned unless stated): Fairfield Imaging Ltd; Fairfield Telepathology Ltd; Geneservice Ltd (75%); Kinetic Imaging Ltd; Medical Solutions FZ LLC (United Arab Emirates); Medical Solutions (London) Ltd (75%); Medical Solutions (Nottingham) Ltd (75%); Pathlore Ltd; Second Opinion Solutions AS (75.3%) (Norway)

Associated Companies: Number One Health Group Ltd (40%)

Principal Banks: The Royal Bank of Scotland plc

Auditors: PricewaterhouseCoopers LLP

Principal Law Firm: Halliwells

Ticker Symbol: SBS

Stock Exchange: London

Status: Public Company

Principal Shareholders: Aberforth Partners (15.68%); Mr S Varkey (8.65%); Mr J Mellon (5.72%); Texas Holdings Limited (5.43%)

No of Employees: 80

Financial Information: Consolidated figures

	31.12.06	31.12.07
	£'000	£'000
Sales turnover	6,025	7,531
(Loss) before tax	(2,332)	(533)
(Loss) after tax	(1,386)	(533)
(Loss) per share	(0.68p)	(0.26p)
Share capital	4,075	4,075
Shareholders' equity	15,427	14,964

03195

SSL INTERNATIONAL PLC

Address: 35 New Bridge Street, London EC4V 6BW

International tel: +44 (20) 7367 5760

International fax: +44 (20) 7367 5790

Telex: 669956

Website: www.ssl-international.com

Company Registration Number: 388828

Board of Directors: Gerald Corbett (Chairman), Garry Watts (Chief Executive Officer), Richard Adam (Non-Executive Director), Ian Adamson (Managing Director, Europe and Americas), Peter Johnson (Non-Executive Director), Mark Moran (Finance Director), Peter Read (Non-Executive Director)

Management: Maria Buxton-Smith (Company Secretary), Paul Doherty (Head of Corporate Affairs), Jan Young (Head of Communications)

PRINCIPAL ACTIVITIES: Manufacture and distribution of healthcare products, barrier contraceptives, footwear and related medical products.

Mergers and Acquisitions: In November 2007 the Group acquired the business and certain assets of Vasyli Australia Pty Ltd, Vasyli (NZ) Ltd, and Vasyli UK Ltd.

Major Products: Scholl footcare and footwear, Durex condoms, Regent Biogel surgical gloves, Marigold household and industrial gloves, OTC products including Syndol, Cuprofen, Resolve, Ralgex, Tubigrip and wound management and continence care products

Trade Names: Adapta, Avanti, Cuprofen, Derbac, Diana, Dio-calm, Dr Scholl, Due In Uno, Durex, Durex Sensation, Eulactol, Fresh Step, Full Marks, Gelactiv, Hydra-Gel, Meltus, Mister Baby, Natruclear, Paramol, Party Feet, Performa, Pescura, Play, Pleasuremax, ProSport, Ralgex, Remegel, Resolve, Sauber, Scholl, Scholl Flight Socks, Syndol, Woodward's

Subsidiary Companies: (100% owned unless stated): LIG China BV (Netherlands); London International GmbH (Germany); London International Group Ltd; London International Norway A/S (Norway); LRC North America Inc (USA); LRC Products Ltd; LRC Products Ticaret ve Pazarlama Ltd Sirketi (Turkey); New Bridge Holdings BV (Netherlands); NV SSSL Healthcare Belgium SA (Belgium); Qingdao London Durex Company Limited (People's Republic of China); Scholl Consumer Products Ltd; Scholl (Investments) Ltd; Scholl Ltd; Scholl (UK) Ltd; Seton Scholl Ireland Holdings (Republic of Ireland); Seton Scholl European Holdings BV (Netherlands); Seton Scholl International Ireland (Republic of Ireland); Simco Ltd; Sonet Investments Ltd; Sonet Prebbles Ltd; Sonet Scholl Overseas Investments Ltd; Sonet Scholl UK Ltd; SSL Americas Inc (USA); SSL Australia Pty Ltd (Australia); SSL Canada Inc (Canada); SSL Ceska Republika sro (Czech Republic); SSL Healthcare Italia SpA (Italy); SSL Healthcare Brands SA (Spain); SSL Healthcare Danmark A/S (Denmark); SSL Healthcare Deutschland GmbH & Co KG (Germany); SSL Healthcare France SA (France); SSL Healthcare GmbH (Germany); SSL Healthcare (Hong Kong) Ltd (Hong Kong SAR); SSL Healthcare Hong Kong Ltd (Hong Kong SAR); SSL Healthcare Ireland Ltd (Republic of Ireland); SSL Healthcare Japan Ltd (Japan); SSL Healthcare Nederland BV (Netherlands); SSL Healthcare (Norge) A/S (Norway); SSL Healthcare Oesterreich GmbH (Austria); SSL Healthcare (Polska) Sp zoo (Poland); SSL Healthcare Singapore Pte Ltd (Singapore); SSL Healthcare Suisse SA (Switzerland); SSL Healthcare Thailand Ltd (Thailand); SSL Hellas SA (Greece); SSL Holdings Inc (USA); SSL Magyarorszag Kft (Hungary); SSL Manufacturing (Thailand) Ltd (Thailand); SSL New Zealand Ltd (New Zealand); SSL Products Ltd; SSL Romania SRL (Romania); SSL Slovensko spol sro (Slovakia); SSL Sverige AB (Sweden); SSL-TTK Ltd (51%) (India); TTK-LIG Ltd (49.87%) (India); Tubifoam Ltd

Principal Banks: Barclays Bank plc

Auditors: KPMG Audit plc

Principal Law Firm: Allen & Overy; Hammonds

Ticker Symbol: SSL

Stock Exchange: London

Status: Public Company

Principal Shareholders: Blackrock Inc (14.94%); Liontrust Investment Services Ltd (5.51%); FMR Corp (5.03%)

No of Employees: 5,350

Financial Information: Consolidated figures

	31.3.07	31.3.08
	£'000	£'000
Sales turnover	477,700	533,900
Profit before tax	46,900	57,400
Profit after tax	33,800	41,300
Dividend	12,400	13,300
Dividend per share	6.8p	7.6p
Earnings (loss) per share	17.0p	(1.5p)
Share capital	19,000	19,100
Shareholders' equity	106,400	125,300